Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Carmustine
Brand Name BiCNU®
Payment Category Medicare Part B
Year Introduced 1977
Type of Drug Nitrosourea
Manufacturer Bristol-Myers Squibb
Medical Affairs Questions (date verified) 877.417.1523
Coverage & Reimbursement Questions 877.517.6326
HCPCS J9050
Billing Unit 100 mg
Medicare Payment Limit (Effective January 1, 2021) $1,743.25

FDA-Approved Indication(s)

  • Indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in: 1) Brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors); 2) Multiple myeloma (in combination with prednisone); 3) Hodgkin's disease (as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy); and 4) Non-Hodgkin's lymphomas (as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy). (10/18/13)

Approved Indication(s) with Orphan Drug Status None
ICD-10 Code(s) for Labeled Indication(s) Malignant neoplasm of brain [C71.x]; Multiple myeloma [C90.0x]; Hodgkin lymphoma [C81.xx]; Non-Hodgkin's lymphomas [C82.xx through C85.xx]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US